Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents

This publication has 25 references indexed in Scilit:

• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
  Blood, 2000
• Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
  Journal of Clinical Investigation, 2000
• In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor
  JNCI Journal of the National Cancer Institute, 1999
• CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins
  Blood, 1997
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
  Nature Medicine, 1996
• Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.
  Proceedings of the National Academy of Sciences, 1995
• RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
  Proceedings of the National Academy of Sciences, 1995
• Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
  Proceedings of the National Academy of Sciences, 1990
• Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
  Science, 1990
• Induction of Chronic Myelogenous Leukemia in Mice by the P210 ^bcr/abl Gene of the Philadelphia Chromosome
  Science, 1990